Prima BioMed Other Non-Current Liabilities 2010-2023 | IMMP

Prima BioMed other non-current liabilities from 2010 to 2023. Other non-current liabilities can be defined as field containing the sum of all non-current liabilities that cannot be standardized into another field as well as those that are aggregated by the company because materially, they are too small to list separately.

Prima BioMed Other Non-Current Liabilities 2010-2023 | IMMP

Prima BioMed other non-current liabilities from 2010 to 2023. Other non-current liabilities can be defined as field containing the sum of all non-current liabilities that cannot be standardized into another field as well as those that are aggregated by the company because materially, they are too small to list separately.
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$178.9B
Regeneron Pharmaceuticals (REGN)$125.5B
Vertex Pharmaceuticals (VRTX)$122.4B
Gilead Sciences (GILD)$104.4B
Bristol Myers Squibb (BMY)$100.8B
CSL (CSLLY)$96.8B
GSK (GSK)$87.9B
Alnylam Pharmaceuticals (ALNY)$35.1B
Argenex SE (ARGX)$31.6B
Biogen (BIIB)$28.8B
BioNTech SE (BNTX)$27.5B
Moderna (MRNA)$26.9B
Illumina (ILMN)$20.9B
BeiGene (BGNE)$19.2B
Genmab (GMAB)$17.3B
BioMarin Pharmaceutical (BMRN)$13.5B
Vaxcyte (PCVX)$13B
Exact Sciences (EXAS)$12.8B
Incyte (INCY)$12.6B
Insmed (INSM)$12.5B
Bio-Techne Corp (TECH)$12.1B
Sarepta Therapeutics (SRPT)$11.9B
QIAGEN (QGEN)$10.4B
Bio-Rad Laboratories (BIO.B)$9.1B
Legend Biotech (LEGN)$9.1B
Roivant Sciences (ROIV)$8.9B
Ascendis Pharma (ASND)$8.7B
Repligen (RGEN)$8B
Halozyme Therapeutics (HALO)$7.9B
Intra-Cellular Therapies (ITCI)$7.9B